Abbott Laboratories Sued Over Heart Valve Failure
A lawsuit alleges a patient's Trifecta GT heart valve failed prematurely after eight years of use.
Updated on Oct. 14, 2026 in Heart Disease
Live Poll
Do you trust that medical device manufacturers are held sufficiently accountable for long-term product failures?
On August 18, 2026, Mark Lynch filed a product liability lawsuit against Abbott Laboratories regarding the failure of a Trifecta GT heart valve. The device, which was implanted for eight years, reportedly failed well before its expected lifespan.
Why it matters
The litigation highlights ongoing concerns over structural valve deterioration in medical devices previously linked to thousands of adverse events. Abbott Laboratories removed the product line from the market in 2023 following reports of premature failure.
The FDA received approximately 3,000 adverse event reports for these heart valves, which were marketed to last 15 to 20 years. The agency linked these specific device failures to nearly 200 deaths.
The players
Mark Lynch
He is the plaintiff who filed a product liability lawsuit against Abbott Laboratories following the failure of his implanted heart valve.
Abbott Laboratories
This global medical device and health care company acquired the Trifecta heart valve product line through its purchase of St. Jude Medical.
FDA
The Food and Drug Administration is the federal agency responsible for overseeing the safety and efficacy of medical devices in the United States.
The details
The Trifecta heart valve was constructed using cow heart tissue mounted on a stent, a design that became a subject of scrutiny due to concerns of premature structural deterioration. The case was moved from California Superior Court to the U.S. District Court for the Central District of California in October 2026.
Timeline
The original Trifecta valve began marketing in 2011.
Abbott Laboratories acquired the product line in 2017.
The valves were removed from the market in July 2023.
Mark Lynch filed the lawsuit on August 18, 2026.
The case was moved to federal court on October 7, 2026.
Health Landscape
This lawsuit follows the precedent set by the July 2023 market removal of Trifecta heart valves by Abbott Laboratories. It reflects a broader shift in accountability for medical devices that exhibit signs of premature structural deterioration over time.
Patients who previously received a Trifecta heart valve may need to consult with their cardiologists regarding the long-term integrity of their implants. The litigation underscores the importance of monitoring for potential symptoms of structural deterioration in heart tissue devices.
The takeaway
Patients with historical heart valve implants should maintain regular diagnostic imaging to monitor for signs of wear. Proactive engagement with medical providers can help identify device performance issues before they result in emergency complications.
Further reading
For more information on the risks associated with cardiac implants, visit the Heart Disease section.
Source note: This article includes information reported by AboutLawsuits.
Live Poll
Do you trust that medical device manufacturers are held sufficiently accountable for long-term product failures?
